1. Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) 
Dorothy Romanus, MSc, Hedy L. Kindler, MD, Laura Archer, MSc, Ethan Basch, MD, Donna Niedzwiecki, PhD, Jane Weeks, MD, Deborah Schrag, MD 
Journal of Pain and Symptom Management 
Volume 43, Issue 2, Pages (February 2012)
DOI: /j.jpainsymman
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
CONSORT (Consolidated Standards of Reporting Trials) diagram of patient enrollment and EQ-5D survey completion in the study.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2 Overall survival by EQ-5D completion status.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Kaplan-Meier survival curves for overall survival (OS) for patients who responded to baseline EQ-5D surveys (n=267). a) OS by baseline EQ-5D index score. b) OS by baseline EQ-5D VAS scores. c) OS by baseline ECOG PS.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Responsiveness of EQ-5D index (dark bars) and VAS (light bars). EQ-5D change scores (y-axis, ×100 for VAS), at eight weeks from baseline, compared with SSQ responses (x-axis) at eight weeks.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5
EQ-5D domain-specific responses. Panels depict percentages of patients reporting any problem at baseline (lightly shaded bars) and at eight weeks (darkly shaded bars) in each listed domain. Percentages of respondents from a sample of the U.S. general population who reported any problems are also shown (dotted bars).
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2012 U.S. Cancer Pain Relief Committee Terms and Conditions